BISMUTH SUBCITRATE POTASSIUM

ID: ALA1201186

Chembl Id: CHEMBL1201186

Max Phase: Approved

First Approval: 2006

Molecular Formula: C12H10BiK3O14

Molecular Weight: 704.47

Molecule Type: Small molecule

Alternative Forms

1. Parent:

   

   ALA1201186

   BISMUTH SUBCITRATE POTASSIUM

Molecule Features

Natural Product: No

Oral: Yes

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: Yes

Prodrug: No

Calculated Properties

Molecular Weight: 704.47

Molecular Weight (Monoisotopic): 703.8786

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Unpublished dataset, 

2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

3. WHO Anatomical Therapeutic Chemical Classification, 

4. Unpublished dataset, 

5. Ni S, Chen X, Yu Q, Xu Y, Hu Z, Zhang J, Zhang W, Li B, Yang X, Mao F, Huang J, Sun Y, Li J, Jia L..  (2020)  Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,  185  [PMID:31732254] [10.1016/j.ejmech.2019.111848]

Source

Source(5):

• Scientific Literature
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• WHO Anatomical Therapeutic Chemical Classification